Studies that evaluated biomarkers in relation to MIS-C indicated that MIS-C's inflammatory response differs from the cytokine storm in severe COVID-19, while sharing similarities with Kawasaki disease, albeit with discrepancies in T cell subsets, IL-17A, and artery damage biomarkers [17]. This evidence concerns the gene IL17A and COVID-19.